Moderna, Inc. (MRNA) Earnings History
Annual and quarterly earnings data from 2016 to 2025
Loading earnings history...
MRNA EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
MRNA Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 55.3% | -158.1% | -145.2% |
| 2024 | 54.2% | -123.3% | -111.3% |
| 2023 | 31.5% | -61.9% | -68.8% |
| 2022 | 71.3% | 49.9% | 44.3% |
| 2021 | 85.2% | 75.0% | 68.8% |
Download Data
Export MRNA earnings history in CSV or JSON format
Free sign-in required to download data
Moderna, Inc. (MRNA) Earnings Overview
As of May 6, 2026, Moderna, Inc. (MRNA) reported trailing twelve-month net income of -$3.19B, reflecting +21.7% year-over-year growth. The company earned $-8.09 per diluted share over the past four quarters, with a net profit margin of -145.2%.
Looking at the long-term picture, MRNA's historical earnings data spans multiple years. The company achieved its highest annual net income of $12.20B in fiscal 2021.
Moderna, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including BNTX (-$1.13B net income, -39.6% margin), NVAX ($440M net income, 39.2% margin), CVAC ($194M net income, 30.3% margin), MRNA has room to improve margins relative to the peer group. Compare MRNA vs BNTX →
MRNA Earnings vs Peers
Earnings metrics vs comparable public companies
MRNA Historical Earnings Data (2016–2025)
10 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$2.82B | +20.8% | -$3.07B | $-7.26 | -145.2% | -158.1% |
| 2024 | -$3.56B | +24.5% | -$3.94B | $-9.27 | -111.3% | -123.3% |
| 2023 | -$4.71B | -156.4% | -$4.24B | $-12.34 | -68.8% | -61.9% |
| 2022 | $8.36B | -31.5% | $9.42B | $20.10 | 44.3% | 49.9% |
| 2021 | $12.20B | +1733.3% | $13.30B | $28.29 | 68.8% | 75.0% |
| 2020 | -$747M | -45.3% | -$763M | $-1.96 | -93.0% | -95.0% |
| 2019 | -$514M | -33.6% | -$546M | $-1.55 | -853.7% | -906.4% |
| 2018 | -$385M | -50.3% | -$469M | $-1.17 | -284.8% | -347.1% |
| 2017 | -$256M | -18.4% | -$269M | $-0.72 | -124.3% | -130.9% |
| 2016 | -$216M | - | -$224M | $-3.79 | -199.5% | -206.4% |
Full MRNA Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
See MRNA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs MRNA Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare MRNA vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonMRNA — Frequently Asked Questions
Quick answers to the most common questions about buying MRNA stock.
Is MRNA growing earnings?
MRNA EPS is $-8.09, with earnings growth accelerating to +21.7%. This exceeds the 5-year CAGR of N/A. TTM net income reached $-3.2B.
What are MRNA's profit margins?
Moderna, Inc. net margin is -145.2%, with operating margin at -158.1%. Below-average margins reflect competitive or cost pressures.
How consistent are MRNA's earnings?
MRNA earnings data spans 2016-2025. The accelerating earnings trend is +21.7% YoY. Historical data enables comparison across business cycles.